GlassScriptPhysician profile
Con Kaleb Newman
NPI 1689396723
$1,708.75
in general payments reported to CMS, 2019-2025
25 companies · $447 in 2025
The $447 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $573 · 2024: $688 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,708.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $227.01 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $211.04 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Otsuka America Pharmaceutical, INC. | $172.49 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $156.43 | 2023-2025 | Auvelity, Sunosi |
| Novo Nordisk INC | $108.49 | 2023-2024 | Ozempic, Rybelsus |
| Amgen INC. | $106.38 | 2023-2024 | Otezla, Repatha, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $105.87 | 2024-2025 | |
| Abbvie INC. | $70.02 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $62.66 | 2024-2025 | Ingrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.60 | 2023-2024 | Jardiance, Tradjenta, Synjardy |
| Lundbeck LLC | $54.41 | 2023-2025 | Vyepti, Rexulti |
| Csl Behring | $51.32 | 2023 | Haegarda |
| Glaxosmithkline, LLC. | $44.44 | 2023-2024 | Shingrix, Arexvy |
| Edwards Lifesciences Corporation | $40.33 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Xeris Pharmaceuticals, INC. | $39.47 | 2023-2024 | Gvoke Hypopen |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $36.26 | 2023 | Accrufer |
| Phathom Pharmaceuticals, INC. | $31.73 | 2024-2025 | Voquezna |
| Organogenesis INC. | $22.04 | 2024 | |
| Medtronic, INC. | $18.35 | 2024 | Venaseal |
| Sumitomo Pharma America, INC. | $18.03 | 2024 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $15.25 | 2024 | |
| Janssen Pharmaceuticals, INC | $15.18 | 2024 | Xarelto |
| Merck Sharp & Dohme LLC | $15.15 | 2025 | Gardasil 9, Capvaxive |
| Ardelyx, INC. | $14.53 | 2025 | Ibsrela |
| Organon LLC | $14.27 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Con Newman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.